Fundraisings and IPOs

Date: 2017-03-20

Type of information: Financing round

Company: Advicenne (France)

Investors: IRDI SORIDEC Gestion (France) Cemag Invest (France) MI Care (Luxembourg) InnoBio (Bpifrance) (France) IXO Private Equity (France) private individuals.

Amount: €16 Million

Funding type: financing round

Planned used: Advicenne plans to use these funds to advance its late-stage pipeline in nephrology and neurology, including: - completion of the Phase III development of ADV7103, which is targeting a renal tubulopathy, an orphan indication. ADV7103 is currently in a pivotal phase III trial in Europe. The Company expects to announce the results of this study during summer 2017; - development of ADV7103 in a second indication targeting another renal disease in Europe; - registration of ADV6209, a paediatric anaesthesiology product outlicensed to Primex Pharmaceuticals in 2016.

Others:

• • On March 20, 2017, Advicenne announced that it has closed a €16 million financing round. The fundraising was led by IRDI SORIDEC Gestion, Cemag Invest and MI Care alongside existing investors InnoBio (Bpifrance) and IXO Private Equity together with private individuals.

Therapeutic area: Rare diseases

Is general: Yes